Company has initiated Phase 2 monotherapy study in trichotillomania and prepares for a Phase 2 add-on therapy study in OCD   Milwaukee, Wisconsin | January 17, […]

Completed 28-patient Phase 2A behavioral biomarker study shows significant improvements in impulse control and 120-patient Phase 2 multi-center study in trichotillomania is fully enrolled

Dr. Chad E. Beyer, Senior Vice President of R&D, will present an overview of results from Promentis’ Phase 2A clinical trial at the 10th annual CNS Summit in Boca Raton Florida.

Dr. Chad E. Beyer will present psychometric findings from the first-ever, multi-center trial conducted in patients with trichotillomania - an impulse control disorder marked by repetitive hairpulling behaviors